10-Q: Medifast Reports Q1 2026 Results, Revenue Declines

Medifast, Inc. reported a significant revenue decrease for the first quarter of 2026, primarily due to a decline in active earning coaches and the ongoing impact of GLP-1 medications.

Summary

• Medifast, Inc. reported a net loss of $2.1 million for the first quarter ended March 31, 2026, compared to a net loss of $0.8 million for the same period in 2025.
• Revenue for the quarter decreased by 34.3% to $76.0 million from $115.7 million in the prior year.
• This decline is attributed to a significant drop in active earning coaches, from 25,400 in Q1 2025 to 14,000 in Q1 2026.
• The company is undergoing a strategic transformation focused on holistic metabolic health, aiming for long-term growth.
• Despite lower sales volume, cost of sales decreased by 22.9%, and selling, general, and administrative (SG&A) expenses decreased by 35.6%.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative report due to significant revenue declines, widening net loss, and a substantial decrease in active coaches, despite some operational efficiencies and a strategic pivot.

Positives

• Revenue per active earning coach increased to $5,432 in Q1 2026 from $4,556 in Q1 2025, indicating greater alignment and efficiency among productive coaches.
• Cost of sales decreased by 22.9% due to lower sales volumes.
• SG&A expenses decreased by 35.6%, driven by lower coach compensation, reduced marketing expenses, and a one-time gain from the sale of a distribution center.
• The company is strategically transforming to focus on the broader metabolic health market, which is believed to be more sustainable.
• Investments in tools, programs, and digital resources to support coaches are ongoing.

Negatives

• Revenue decreased by 34.3% to $76.0 million in Q1 2026 compared to $115.7 million in Q1 2025.
• Net loss widened to $2.1 million in Q1 2026 from $0.8 million in Q1 2025.
• The number of active earning coaches significantly decreased to 14,000 from 25,400 year-over-year.
• Gross profit margin decreased to 68.1% from 72.8% due to loss of leverage on fixed costs.
• Loss from operations increased to $3.3 million from $1.3 million.

Risks

• Continued pressure with client acquisition reflecting broader challenges in the operating environment, including rapid adoption of GLP-1 medications for weight loss.
• Expectation that the number of active earning coaches will continue to decline in 2026.
• Macroeconomic uncertainty and volatility, including the impact of inflation and tariffs, could affect cost structure and consumer spending.
• Potential for changes in tariff regulations to affect the cost and availability of certain raw materials.
• Competition from a wide variety of metabolic health and weight loss products and programs, including GLP-1 medications.

Future Outlook

The company expects the number of active earning coaches to continue to decline in 2026. Medifast plans to launch significant product innovations, incorporating next-generation ingredients for metabolic enhancement, with an updated product line expected to market this year. The company aims to address the needs of a broader metabolic health market with a long-term growth strategy.

Management Comments

• The Company started 2026 by moving from transformation to execution, leveraging its extensive experience in structured weight loss coupled with recent scientific research and enhanced product offerings to address the needs of a broader metabolic health market.
• While GLP-1 medication usage continues to accelerate, medication alone may not be adequate. Recent research indicates that approximately one-third of users discontinue the medication after six months, and up to 74% stop after a year. Furthermore, studies show that two-thirds of weight lost on GLP-1 medications is typically regained within 12 months of stopping treatment, with cardiometabolic benefits often reversing as well.
• Given that GLP-1 medications are shown to be most effective when combined with lifestyle changes, we see strong alignment with our expertise in helping people create durable habits through coach-supported, behavior-based systems.
• We believe Medifast is uniquely positioned to serve a broader range of clients and lead the advancement of metabolic health through its personalized coaching, community support, and science-backed nutrition solutions.

Industry Context

StockSavvy.ai notes that Medifast's strategic shift towards holistic metabolic health aligns with a growing industry trend recognizing the limitations of solely focusing on weight loss and the increasing awareness of metabolic dysfunction. The company's emphasis on coach-supported, behavior-based systems positions it to complement the use of GLP-1 medications, which are proving most effective when combined with lifestyle changes.

Comparison to Industry Standards

• The company's gross profit margin of 68.1% for Q1 2026 is lower than the 72.8% reported in Q1 2025, indicating potential pressure on pricing or increased cost of goods sold relative to revenue.
• The decline in revenue by 34.3% is a significant underperformance compared to the broader health and wellness sector, which has seen varied growth depending on specific niches.
• The increase in revenue per active earning coach suggests an improvement in the productivity of the remaining coach network, which is a positive sign for operational efficiency within the direct selling model.
• The company's strategy to address the limitations of GLP-1 medications by integrating them with lifestyle changes is a novel approach in the competitive weight loss market, potentially differentiating it from competitors solely focused on product sales or medication.
• The company's focus on 'Metabolic Synchronization' and preserving lean mass while burning visceral fat aligns with emerging scientific understanding of metabolic health, positioning it at the forefront of evidence-based wellness solutions.

Legal Proceedings

• The Company is, from time to time, subject to a variety of litigation and similar proceedings that arise out of the ordinary course of its business. Based upon the Company's experience, current information, and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its results of operations, financial position, or liquidity. However, the results of legal actions cannot be predicted with certainty.

Stakeholder Impact

• Shareholders: Negative impact due to decreased revenue, increased net loss, and a decline in the number of active earning coaches, potentially affecting future profitability and stock value.
• Employees: Potential impact from cost-saving measures, including a decrease in employee compensation and realignment of the employee base.
• Coaches: Negative impact from the significant decrease in active earning coaches and ongoing challenges in client acquisition, although revenue per coach has increased.
• Customers: May benefit from the company's strategic focus on holistic metabolic health and potential new product innovations, but may also be influenced by the broader adoption of GLP-1 medications.

Next Steps

• Launch significant product innovations, incorporating next-generation ingredients for metabolic enhancement.
• Bring an updated product line to market this year.
• Continue to invest strategically in tools, programs, and digital resources to support coaches.
• Continue to enhance digital tools to support business management of coaches.
• Continue to monitor and adapt to macroeconomic conditions and competitive landscape.

Key Dates

Recommendation

While the Q1 2026 results show significant deterioration with declining revenue and widening losses, the company's strategic pivot towards the growing metabolic health market and its efforts to complement GLP-1 medications offer potential for future recovery. The increase in revenue per coach suggests operational improvements within the existing network. However, the continued decline in active coaches and the competitive landscape warrant a cautious 'hold' until a clear turnaround is demonstrated.

Keywords

Medifast, OPTAVIA, Quarterly Report, 10-Q, Metabolic Health, Weight Loss, Coaches, Revenue, Net Loss, GLP-1 Medications